1. World Health Organization. World report on vision. 2019. https://www.who.int/publications/i/item/9789241516570
2. Ang M, Wong TY. Updates on Myopia: A Clinical Perspective. Springer Nature; 2020. https://link.springer.com/book/10.1007/978-981-13-8491-2
3. Wong YL, Sabanayagam C, Ding Y, et al. Prevalence, risk factors, and impact of myopic macular degeneration on visual impairment and functioning among adults in Singapore. Invest Ophthalmol Vis Sci. 2018;59(11):4603–13
4. Wu PC, Chuang MN, Choi J, Chen H, Wu G, Ohno-Matsui K, Jonas JB, Cheung CM. Update in myopia and treatment strategy of atropine use in myopia control. Eye. 2019 Jan;33(1):3-13.
5. Zhao Y, Feng K, Liu RB, Pan JH, Zhang LL, Xu ZP, Lu XJ. Atropine 0.01% eye drops slow myopia progression: a systematic review and Meta-analysis. Int J Ophthalmol 2019;12(8):1337-1343
6. Larkin GL, Tahir A, Epley KD, Beauchamp CL, Tong JT, Clark RA. Atropine 0.01% Eye Drops for Myopia Control in American Children: A Multiethnic Sample Across Three US Sites. Ophthalmol Ther. 2019 Dec;8(4):589-598. doi: 10.1007/s40123-019-00217-w.
7. Wei S, Li SM, An W, Du J, Liang X, Sun Y, Zhang D, Tian J, Wang N. Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children: a randomized clinical trial. JAMA ophthalmology. 2020 Nov 1;138(11):1178-84.
8. Khanal S, Phillips JR. Which low‐dose atropine for myopia control?. Clinical and Experimental Optometry. 2020 Mar 1;103(2):230-2.
9. Yam JC, Zhang XJ, Zhang Y, Wang YM, Tang SM, Li FF, Kam KW, Ko ST, Yip BH, Young AL, Tham CC. Three-Year clinical trial of low-concentration atropine for myopia progression (lamp) study: continued versus washout: phase 3 report. Ophthalmology. 2022 Mar 1;129(3):308-21.